📋 Executive Summary
Today's major developments are centered on late-stage clinical and regulatory successes. The FDA approved two significant therapies: Rocket Pharmaceuticals' gene therapy, Kresladi, for a rare immune disease, and Novo Nordisk's first-in-class once-weekly insulin for type 2 diabetes. Concurrently, several large-cap pharma companies, including Takeda, AstraZeneca, and Novocure, reported positive Phase 3 data in high-impact indications like psoriasis, COPD, and pancreatic cancer, signaling strong pipeline momentum across the industry.
⚡ Top Events Today
Novo Nordisk Secures FDA Approval for First Once-Weekly Insulin for Type 2 Diabetes
The FDA approved the first once-weekly basal insulin alternative to daily injections for the treatment of type 2 diabetes.
Rocket Pharma's Gene Therapy Kresladi Gains Accelerated FDA Approval for Rare Immune Disease
Received accelerated FDA approval for its hematopoietic stem cell-based gene therapy for children with severe leukocyte adhesion deficiency-1, following a previous rejection due to manufacturing issues.
Takeda's $4B Psoriasis Bet Pays Off with Positive Phase 3 Data
A psoriasis asset, acquired for $4 billion, met its endpoints in a Phase 3 trial, clearing the path for a potential FDA submission.
AstraZeneca's COPD Candidate Succeeds in Phase 3, Reviving Drug Class
The drug candidate successfully met its endpoints in a pair of Phase 3 trials, demonstrating broad efficacy.
Novocure Reports Positive Data for Electric Field Therapy in Metastatic Pancreatic Cancer
The company reported positive clinical data for its electric field-based treatment in metastatic pancreatic cancer.
📁 All Events (13497 stories)
AROA Biosurgery Limited announced the completion of its randomised controlled trial (RCT) for Symphony. A preliminary read-out indicates that the trial successfully achieved its primary endpoint.
AROA Biosurgery Limited announced the completion of its randomised controlled trial (RCT) for Symphony. A preliminary read-out indicates that the trial successfully achieved its primary endpoint.
Takeda has posted positive phase 3 data for an autoimmune asset targeting psoriasis, which it acquired for $4 billion. This data clears the path for a potential FDA submission, positioning Takeda to compete with companies like Bristol Myers Squibb and Johnson & Johnson for market share.
Takeda has posted positive phase 3 data for an autoimmune asset targeting psoriasis, which it acquired for $4 billion. This data clears the path for a potential FDA submission, positioning Takeda to compete with companies like Bristol Myers Squibb and Johnson & Johnson for market share.
Tanabe Pharma announced positive data from a Phase 3 trial of its oral drug for rare diseases causing pain upon light exposure. This represents the company's first major clinical milestone since its acquisition by Bain Capital.
Tanabe Pharma announced positive data from a Phase 3 trial of its oral drug for rare diseases causing pain upon light exposure. This represents the company's first major clinical milestone since its acquisition by Bain Capital.
Rocket received accelerated FDA approval for its hematopoietic stem cell-based gene therapy, Kresladi (marnetegragene autotemcel). This approval is for the treatment of certain children with severe leukocyte adhesion deficiency-1.
Rocket received accelerated FDA approval for its hematopoietic stem cell-based gene therapy, Kresladi (marnetegragene autotemcel). This approval is for the treatment of certain children with severe leukocyte adhesion deficiency-1.
Novocure reported positive clinical data for its electric field-based treatment in metastatic pancreatic cancer. This announcement follows an earlier FDA approval for the same treatment in local pancreatic cancer.
Novocure reported positive clinical data for its electric field-based treatment in metastatic pancreatic cancer. This announcement follows an earlier FDA approval for the same treatment in local pancreatic cancer.
The US FDA has approved the first generic version of fluticasone propionate inhalation aerosol, which is a generic equivalent to Flovent HFA. This approval is specifically for the maintenance treatment of asthma.
The US FDA has approved the first generic version of fluticasone propionate inhalation aerosol, which is a generic equivalent to Flovent HFA. This approval is specifically for the maintenance treatment of asthma.
AstraZeneca's chronic obstructive pulmonary disease (COPD) drug candidate successfully met its endpoints in a pair of Phase 3 trials. The drug demonstrated broad efficacy, providing positive results for a class that has previously seen mixed data from competitors like Roche and Sanofi.
AstraZeneca's chronic obstructive pulmonary disease (COPD) drug candidate successfully met its endpoints in a pair of Phase 3 trials. The drug demonstrated broad efficacy, providing positive results for a class that has previously seen mixed data from competitors like Roche and Sanofi.
The FDA approved Novo Nordisk's once-weekly insulin for type 2 diabetes. This is the first US-approved longer-acting alternative to daily basal treatment for this indication.
The FDA approved Novo Nordisk's once-weekly insulin for type 2 diabetes. This is the first US-approved longer-acting alternative to daily basal treatment for this indication.
The FDA granted accelerated approval to Rocket Pharmaceuticals' gene therapy for an ultra-rare immune disease on Thursday. This approval follows an earlier rejection for manufacturing problems.
The FDA granted accelerated approval to Rocket Pharmaceuticals' gene therapy for an ultra-rare immune disease on Thursday. This approval follows an earlier rejection for manufacturing problems.
The European Medicines Agency's human medicines committee (CHMP) recommended the approval of a new subcutaneous form of Sanofi's multiple myeloma drug, Sarclisa. CHMP also recommended four other new drugs for approval.
The European Medicines Agency's human medicines committee (CHMP) recommended the approval of a new subcutaneous form of Sanofi's multiple myeloma drug, Sarclisa. CHMP also recommended four other new drugs for approval.
Corcept's first-in-class drug, Lifyorli, gained FDA approval for ovarian cancer. It can be prescribed alongside nab-paclitaxel for patients who have relapsed one-to-three times.
Corcept's first-in-class drug, Lifyorli, gained FDA approval for ovarian cancer. It can be prescribed alongside nab-paclitaxel for patients who have relapsed one-to-three times.
Kodiak Sciences announced positive topline results from its GLOW2 Phase 3 study in diabetic retinopathy. Zenkuda (tarcocimab tedromer) demonstrated superiority over sham, with 62.5% of treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% in the sham group.
Kodiak Sciences announced positive topline results from its GLOW2 Phase 3 study in diabetic retinopathy. Zenkuda (tarcocimab tedromer) demonstrated superiority over sham, with 62.5% of treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% in
EMA Approval: Orathecin (EuroGen Pharmaceuticals Ltd)
Active substance: rubitecan | EC Decision: 31/12/2009 | Status: Application withdrawn | Flags: Orphan | Area: Pancreatic Neoplasms
EMA Approval: Surfaxin (Pharm Research Associates (UK) Limited)
Active substance: sinapultide;Dipalmitoylphosphatidylcholine;palmitoyl-oleoyl phosphatidylglycerol;palmitic acid | EC Decision: 31/12/2009 | Status: Application withdrawn | Flags: Orphan | Area: Respiratory Distress Syndrome, Newborn
EMA Approval: Voraxaze (Protherics PLC)
Active substance: glucarpidase | EC Decision: 31/12/2009 | Status: Application withdrawn | Flags: Orphan | Area:
EMA Approval: Cerepro (Ark Therapeutics)
Active substance: adenovirus-mediated Herpes simplex virus-thymidine kinase gene | EC Decision: 31/12/2009 | Status: Application withdrawn | Flags: Orphan | Area: Glioma
EMA Approval: Retisert (Bausch Lomb Ireland)
Active substance: Fluocinolone acetonide | EC Decision: 31/12/2009 | Status: Application withdrawn | Flags: Orphan | Area:
EMA Approval: Mylotarg (Wyeth Europa Ltd)
Active substance: gemtuzumab ozogamicin | EC Decision: 24/01/2008 | Status: Refused | Flags: Orphan | Area: Leukemia, Myeloid, Acute
EMA Approval: Kiacta (Neurochem Luxco II SARL)
Active substance: eprodisate disodium | EC Decision: 31/12/2009 | Status: Application withdrawn | Flags: Orphan | Area: Amyloidosis